Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 10/20 | 0.77 |
| ▸ | MEN1 | O00255 | 14/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 14/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.72 |
| ▸ | MAPT | P10636 | 11/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 0.72 |
| ▸ | BLM | P54132 | 9/20 | 0.72 |
| ▸ | HPGD | P15428 | 8/20 | 0.72 |
| ▸ | RECQL | P46063 | 7/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.72 |
| ▸ | PKM | P14618 | 6/20 | 0.72 |
| ▸ | THRB | P10828 | 5/20 | 0.72 |
| ▸ | NR4A1 | P22736 | 5/20 | 0.72 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.72 |
| ▸ | BID | P55957 | 1/20 | 0.72 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 12/20 | 0.65 |
| ▸ | USP2 | O75604 | 3/20 | 0.65 |
| ▸ | HTT | P42858 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24277667 | 0.87 | MCL1 (1.00) | MCL1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL13856422 | 0.84 | MEN1 (1.00) | MCL1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL26295896 | 0.82 | MCL1 (0.82) | MCL1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL20919142 | 0.82 | MEN1 (0.72) | MCL1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL30518187 | 0.82 | MEN1 (0.72) | MCL1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL24277665 | 0.81 | MCL1 (0.80) | MCL1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL24277194 | 0.81 | MCL1 (0.80) | MCL1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL15814086 | 0.80 | MEN1 (0.84) | MCL1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL2113647 | 0.79 | ALDH1A1 (1.00) | MCL1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL13856578 | 0.79 | MEN1 (1.00) | MCL1MEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183236-B2 | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183236-B2 | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | TYMP, IMPDH1, SAMHD1 | MCL1 2029/4885MEN1 4601/4885KMT2A 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.